Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Goodwill (2021 - 2023)

InMed Pharmaceuticals has reported Goodwill over the past 3 years, most recently at $1.1 million for Q2 2023.

  • For Q2 2023, Goodwill fell 5.79% year-over-year to $1.1 million; the TTM value through Jun 2023 reached $1.1 million, down 5.79%, while the annual FY2023 figure was $1.1 million, 5.79% down from the prior year.
  • Goodwill for Q2 2023 was $1.1 million at InMed Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Over five years, Goodwill peaked at $2.0 million in Q4 2021 and troughed at $1.1 million in Q2 2023.
  • A 3-year average of $1.6 million and a median of $1.7 million in 2021 define the central range for Goodwill.
  • Biggest five-year swings in Goodwill: crashed 34.14% in 2022 and later decreased 5.79% in 2023.
  • Year by year, Goodwill stood at $2.0 million in 2021, then tumbled by 43.47% to $1.1 million in 2022, then dropped by 5.79% to $1.1 million in 2023.
  • Business Quant data shows Goodwill for INM at $1.1 million in Q2 2023, $1.1 million in Q2 2022, and $2.0 million in Q1 2022.